Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison (TACE-hypoRT)

Civil Hospices of Lyon

Status: Completed

Conditions: Non-metastatic Hepatocellular Carcinoma

Treatments: Other: TACE + hypofractionated EBRT; Procedure: Surgical resection

Study type: Observational

Funder types: Other

Identifiers

NCT04823715

249

Details and patient eligibility

About

Patients with non-metastatic unresectable hepatocellular carcinoma

Enrollment: 163 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥18 years of age
• ECOG 0-2
• Histologically proven hepatocellular carcinoma or proven according to radiological and biochemical criteria (EASL-AASLD) in cirrhotic patients
• Child-Pugh class A
• Absence of truncular or lobar portal vein invasion, or suprahepatic vein invasion

Exclusion criteria

• Uncontrolled replication of hepatitis B virus
• Transplanted liver
• Previous abdominal irradiation
• Previous treatment of HCC with systemic therapy, or with surgical resection in the 2 previous years
• Metastatic illness

Trial design

163 participants in 2 patient groups

TACE- hypofractionated radiation therapy

Description:

Patients will receive one course of transarterial chemoembolization followed 1 to 4 weeks later by hypofractionated radiation therapy up to a total dose of 45 to 60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.

Treatment:

Other: TACE + hypofractionated EBRT

Surgical resection

Description:

Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma

Treatment:

Procedure: Surgical resection